Jun 2026 (Q2 FY26) — Aug 3, 2026
Compugen Q2 FY26 — Pipeline and Partnership Progress
Read the full callCompugen (CGEN) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
Compugen earnings: last reported Mon, 3 Aug 2026, for the quarter ended Jun 2026.
Price
$1.97 +0.51% · +$0.01
Performance +4.8% 1Y
1Y: $1.88 on 17 Oct 2025 → $1.97. High $3.1 (24 Apr 2026), low $1.47 (29 Dec 2025).
- Previous close
- $1.96
- 52-week range
- $1.47 – $3.1
- One year
- +7.07%
Overview
- Symbol
- CGEN
- Sector
- Health Care
- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Compugen earnings calls (CGEN)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -331 | -358 | -388 | -422 | -456 | -475 | -489 | -453 |
| Total liabilities | 16 | 15 | 19 | 25 | 16 | 56 | 60 | 54 |
| Fixed assets | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Investments | — | — | — | — | 0 | 12 | 24 | 9 |
| Total assets | 53 | 54 | 138 | 132 | 94 | 121 | 115 | 157 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13 | -28 | -28 | -23 | -34 | -36 | 50 | 32 |
| Cash from investing | -35 | 5 | -82 | 7 | 37 | 36 | -46 | 30 |
| Cash from financing | 28 | 26 | 108 | 17 | 0 | 3 | 1 | 11 |
| Net cash flow | — | — | — | 1 | 3 | 3 | 4 | 72 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Free cash flow | -13 | -28 | -28 | -23 | -35 | -36 | 49 | 31 |
Insider filings
34 filings between Mar 26, 2026 and Jul 29, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$118.3K
11 sales by 2 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 9
- Award — granted as compensation
- 14
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Levine Zurit | — | $75.3K | Jul 9, 2026 |
| Ophir Eran | — | $42.9K | Apr 24, 2026 |
Latest filings (34)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 29, 2026 | Mahler Michelle Chief Medical Officer | Award | 13,500 | $0 |
| Jul 29, 2026 | ZWEIFACH SANFORD S Director | Award | 7,500 | $0 |
| Jul 29, 2026 | Halevy Gilead Director | Award | 7,500 | $0 |
| Jul 29, 2026 | Hukkelhoven Mathias Director | Award | 7,500 | $0 |
| Jul 29, 2026 | Livnat Savitzky Kinneret Director | Award | 7,500 | $0 |
| Jul 29, 2026 | Kredo Russo Sharon SVP, Research & Discovery | Award | 18,000 | $0 |
| Jul 29, 2026 | Perry Eran Director | Award | 7,500 | $0 |
| Jul 29, 2026 | Silberman David Chief Financial Officer | Award | 19,500 | $0 |
| Jul 29, 2026 | Levine Zurit SVP, Business Development | Award | 18,000 | $0 |
| Jul 9, 2026 | Levine Zurit SVP, Business Development | Sale 10b5-1 plan | 1,875 | $4.7K |
| Jul 9, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 1,875 | $1.6K |
| Apr 24, 2026 | Ophir Eran President and CEO | Option exercise 10b5-1 plan | 5,000 | $4.1K |
| Apr 24, 2026 | Ophir Eran President and CEO | Sale 10b5-1 plan | 5,000 | $16.0K |
| Apr 24, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 2,000 | $2.3K |
| Apr 24, 2026 | Levine Zurit SVP, Business Development | Sale 10b5-1 plan | 2,000 | $6.4K |
| Apr 14, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 2,000 | $2.3K |
| Apr 14, 2026 | Levine Zurit SVP, Business Development | Sale 10b5-1 plan | 2,000 | $5.6K |
| Apr 14, 2026 | Ophir Eran President and CEO | Option exercise 10b5-1 plan | 5,000 | $4.1K |
| Apr 14, 2026 | Ophir Eran President and CEO | Sale 10b5-1 plan | 5,000 | $14.5K |
| Apr 10, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 1,125 | $933 |
| Apr 10, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 2,000 | $2.3K |
| Apr 10, 2026 | Levine Zurit SVP, Business Development | Sale 10b5-1 plan | 3,125 | $8.0K |
| Apr 8, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 4,375 | $3.6K |
| Apr 8, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 1,000 | $1.1K |
| Apr 8, 2026 | Levine Zurit SVP, Business Development | Sale 10b5-1 plan | 5,375 | $13.0K |
| Apr 7, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 2,500 | $2.1K |
| Apr 7, 2026 | Levine Zurit SVP, Business Development | Sale 10b5-1 plan | 2,500 | $5.8K |
| Apr 1, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 1,000 | $1.1K |
| Apr 1, 2026 | Levine Zurit SVP, Business Development | Sale 10b5-1 plan | 3,500 | $7.7K |
| Apr 1, 2026 | Ophir Eran President and CEO | Option exercise 10b5-1 plan | 5,625 | $4.7K |
| Apr 1, 2026 | Ophir Eran President and CEO | Sale 10b5-1 plan | 5,625 | $12.4K |
| Apr 1, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 2,500 | $2.1K |
| Mar 26, 2026 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 plan | 11,875 | $9.8K |
| Mar 26, 2026 | Levine Zurit SVP, Business Development | Sale 10b5-1 plan | 11,875 | $24.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for COMPUGEN LTD
Free account. Everything above stays public.
Write why you follow COMPUGEN LTD and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading